Springworks patents expiration
1. Ogsiveo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951958 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Mar, 2025
(10 months from now) | |
| US7795447 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Aug, 2025
(1 year, 3 months from now) | |
| US7342118 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Aug, 2025
(1 year, 3 months from now) | |
| US10710966 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| US11845732 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| US10590087 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| US10941118 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11820748 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| US11504354 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(18 years from now) | |
| US11612588 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(18 years from now) | |
| US11844780 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(18 years from now) | |
| US11807611 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-452) | Nov 27, 2030 |
| New Chemical Entity Exclusivity(NCE) | Nov 27, 2028 |
Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient
NCE-1 date: 28 November, 2027
Market Authorisation Date: 27 November, 2023
Treatment: Treatment of adult patients with progressing desmoid tumors
Dosage: TABLET;ORAL
More Information on Dosage
OGSIVEO family patents
